Table 1. Clinical manifestation of ULCD, ESS, and LMS.
| Clinical manifestation | ULCD (n=30) | MPMUT (n=33) | p-value | ||
|---|---|---|---|---|---|
| ESS (n=18) | LMS (n=15) | ||||
| Age (yr) | 45.5±10.1 | 42.9±11.3 | 56.9±13.3 | 0.005* | |
| Menopause status | 0.009† | ||||
| Non-menopausal | 27 (90.0) | 15 (83.3) | 4 (26.7) | 0.821‡ | |
| Menopausal | 3 (10.0) | 3 (16.7) | 11 (73.3) | <0.001§ | |
| Tumor marker | |||||
| CA 125 (U/mL) | 35.7±58.4 | 45.6±78.8 | 89.7±204.2 | 0.450* | |
| CEA (ng/mL) | 1.1±0.7 | 1.1±0.9 | 1.4±0.9 | 0.365* | |
| CA 19-9 (U/mL) | 39.9±141.0 | 16.2±12.0 | 184.8±632.6 | 0.381* | |
| Symptom | |||||
| Asymptomatic | 17 (56.7) | 6 (33.3) | 3 (20.0) | 0.034† | |
| Vaginal bleeding | 1 (3.3) | 7 (38.9) | 4 (26.7) | 0.204‡ | |
| Abdominal pain | 6 (20.0) | 3 (16.7) | 2 (13.3) | 0.043§ | |
| Abdominal mass | 6 (20.0) | 2 (11.1) | 6 (40.0) | ||
| Initial surgery type | |||||
| Exploratory laparotomy | 0 (0.0) | 2 (11.1) | 4 (26.7) | 0.022† | |
| Total hysterectomy | 20 (66.7) | 11 (61.1) | 11 (73.3) | 0.173‡ | |
| Myomectomy | 10 (33.3) | 5 (27.8) | 0 (0.0) | 0.001§ | |
| Malignancy suspicion | 0.029† | ||||
| Yes | 9 (30.0) | 9 (50.0) | 11 (73.3) | 0.281‡ | |
| No | 21 (70.0) | 9 (50.0) | 4 (26.7) | 0.014§ | |
Except where indicated, data are numbers of patients or mean±standard deviation and numbers in parenthesis are percentages.
CA, cancer antigen; CEA, carcinoembryonic antigen; ESS, endometrial stromal sarcoma; LMS, leiomyosarcoma; MPMUT, malignant pure mesenchymal uterine tumor; ULCD, uterine leiomyoma with cystic degeneration.
*One-way analysis of variance; †χ2 test, ULCD vs. MPMUT; ‡χ2 test, ULCD vs. ESS; §χ2 test, ULCD vs. LMS.